WVE241220P22500
- 0.00
- 0.000.00%
Wave Life Sciences Newsroom
Insider Sale: President and CEO of $WVE (WVE) Sells 50,000 Shares
Wave Life Sciences CEO Paul Bolno Sells $750,000 in Shares
Truist Financial Maintains Wave Life Sciences(WVE.US) With Buy Rating
Wave Life Sciences to Present at Upcoming Investor Conferences
In 2025, US Biotech stocks are expected to rise significantly. jpmorgan's top pick is vertex pharmaceuticals (VRTX.US).
Vertex pharmaceuticals (Vertex) ranked first on the list of US biotechnology stock selections for 2025 released by jpmorgan.
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
Wave Life Sciences Is Maintained at Outperform by Mizuho
Mizuho Securities Maintains Wave Life Sciences(WVE.US) With Buy Rating, Announces Target Price $22
Express News | Wave Life Sciences Ltd : Mizuho Raises Target Price to $22 From $19
Earnings Update: Here's Why Analysts Just Lifted Their Wave Life Sciences Ltd. (NASDAQ:WVE) Price Target To US$22.20
Wave Life Sciences Third Quarter 2024 Earnings: Misses Expectations
B.Riley Financial Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $22
A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $20 to $36
Positive FDA Feedback and Strategic Advancements Boost Wave Life Sciences' Investment Potential in Huntington's Disease
Wave Life Sciences' Q3 2024 Advances in RNA Therapies
Wave Life Sciences | 8-K: Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Wave Life Sciences | 10-Q: Q3 2024 Earnings Report
Wave Life Sciences Ltd. (WVE) Q3 2024 Earnings Call Transcript Summary
Wave Life Sciences: Promising Advancements and Strategic Growth Potential Drive Buy Rating
Wave Life Sciences Price Target Raised to $36 From $17 at Truist